Hiroshi Wataya

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema.

Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema.

Journal: Respirology (Carlton, Vic.)

Published: February 04, 2026

Mortality and exacerbation risk according to GOLD and STAR severity stages of COPD: a 5-year multicenter prospective cohort study.

Mortality and exacerbation risk according to GOLD and STAR severity stages of COPD: a 5-year multicenter prospective cohort study.

Journal: Scientific reports

Published: April 23, 2025

Update of prognosis and characteristics of chronic obstructive pulmonary disease in a real-world setting: a 5-year follow-up analysis of a multi-institutional registry.

Update of prognosis and characteristics of chronic obstructive pulmonary disease in a real-world setting: a 5-year follow-up analysis of a multi-institutional registry.

Journal: BMC pulmonary medicine

Published: March 08, 2024

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry.

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry.

Journal: BMJ open respiratory research

Published: June 01, 2023

Interpleural distance predicts persistent air leak after initial primary spontaneous pneumothorax.

Interpleural distance predicts persistent air leak after initial primary spontaneous pneumothorax.

Journal: Journal of thoracic disease

Published: July 10, 2020

Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.

Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.

Journal: The oncologist

Published: April 17, 2020

Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408.

Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408.

Journal: Journal of clinical medicine

Published: November 11, 2019

Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.

Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 07, 2019

Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer.

Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer.

Journal: OncoTargets and therapy

Published: November 11, 2017

A saccular superior vena cava aneurysm with unique diagnostic computed tomography findings.

A saccular superior vena cava aneurysm with unique diagnostic computed tomography findings.

Journal: Respirology case reports

Published: June 13, 2017

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.

Journal: Oncotarget

Published: February 15, 2017

Emphysematous Pyelonephritis and Cystitis: Unusual Adverse Events during Concurrent Chemoradiotherapy for Lung Cancer.

Emphysematous Pyelonephritis and Cystitis: Unusual Adverse Events during Concurrent Chemoradiotherapy for Lung Cancer.

Journal: Case reports in oncology

Published: February 14, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026